Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release
Irma H Benedek, Janet Jobes, Qinfang Xiang, William D Fiske Endo Pharmaceuticals Inc, Chadds Ford, PA, USA Background: A formulation of crush-resistant extended-release opioids may deter abuse. The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and...
Saved in:
Main Authors: | Fiske WD (Author), Xiang Q (Author), Jobes J (Author), Benedek IH (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2011-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review of oral oxymorphone in the management of pain
by: Paul Sloan
Published: (2008) -
Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C
by: Hassan Mehmood MD, et al.
Published: (2018) -
Development and bioequivalence study of potassium chloride extended release tablets
by: Thu Van Le Thi, et al.
Published: (2018) -
Bioequivalence and Pharmacokinetics Comparison of Two Formulations of Extended-Release Pentoxifylline Tablets in Healthy Subjects after Fasting and Fed Conditions
by: Jaafar J. Ibraheem Al-Tamimi
Published: (2017) -
Bioequivalence and Pharmacokinetics Comparison of Two Formulations of Extended-Release Pentoxifylline Tablets in Healthy Subjects after Fasting and Fed Conditions
by: Jaafar J. Ibraheem Al-Tamimi
Published: (2017)